Bicara Therapeutics Inc.
BCAX
$14.81
$0.271.86%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Net Income | -68.46% | 23.48% | -76.99% | -76.99% | |
| Total Depreciation and Amortization | 7.14% | 650.00% | 766.67% | 766.67% | |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | |
| Total Other Non-Cash Items | 100.90% | -84.87% | 260.19% | 260.19% | |
| Change in Net Operating Assets | -507.44% | -18.89% | 97.46% | 97.46% | |
| Cash from Operations | -273.72% | -63.54% | -1.61% | -1.61% | |
| Capital Expenditure | 90.83% | 94.67% | -- | -- | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | -- | -- | -- | -- | |
| Cash from Investing | 90.83% | 94.67% | -- | -- | |
| Total Debt Issued | -- | -- | -- | -- | |
| Total Debt Repaid | -- | -- | -- | -- | |
| Issuance of Common Stock | -- | 396,970.24% | 2,156.92% | 2,156.92% | |
| Repurchase of Common Stock | -- | -- | -- | -- | |
| Issuance of Preferred Stock | -- | -- | -- | -- | |
| Repurchase of Preferred Stock | -- | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | -- | -- | -- | -- | |
| Cash from Financing | -100.50% | 737.39% | -97.70% | -97.70% | |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | -116.67% | 984.54% | -345.43% | -345.43% | |